Top Pharmaceutical Companies (2,038)
Shionogi B.V. (known as “Shionogi Europe”) is the European headquarters of Shionogi & Co., Ltd, a leading global research-driven pharmaceutical company based in Osaka, Japan. Since 1878, Shionogi has been striving to supply the best possible medicines to protect the health and wellbeing of the patients we serve. We are dedicated to finding innovative solutions for pressing unmet clinical needs,...
Vitabiotics is a leading British nutraceutical company founded in 1971, specializing in the development and manufacturing of science-based vitamin and mineral supplements. Known for brands like Pregnacare, Wellman, and Perfectil, the company focuses on nutritional healthcare for various life stages. It is recognized as the UK's number one vitamin company, committed to rigorous clinical research and innovation, with a global...
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts,...
Alcon's Top Stability & Growth Strengths
Strong Market Position & Advantage: The business is positioned as a global leader in eye care with meaningful share in contact lenses and one of the largest installed bases in ophthalmic surgical equipment, supporting durable demand across geographies. Scale across Vision Care and Surgical also supports recurring revenue via consumables tied to the installed base.
Resilient & Sustainable Growth: Revenue is described as growing year over year with guidance calling for continued mid-single-digit constant-currency sales growth into 2026, supported by steady demand for essential procedures like cataract surgery. The company is also positioned to outpace broader eye-care market growth expectations per the provided outlook.
Healthy Cash Flow: Cash generation is described as strong, with operating cash flow and free cash flow at sizable levels that support ongoing investment and shareholder returns. This cash profile provides resilience against near-term cost headwinds and funding for launches and efficiency programs.
Medical Leverage is a communications company that partners with pharmaceutical, biotech, and medical device companies to promote products and services through education, specializing in KOL and peer-to-peer management, digital formatting, medical education, medical writing, and premarket launch planning.
Navigo Proteins GmbH is a growing, innovative biotech company based in Germany. It focuses on advancing the next generation of biotherapeutics through proprietary protein engineering technologies. The company specializes in creating and optimizing proprietary protein ligands for affinity chromatography and precision medicine, delivering impactful solutions across the biotherapeutics value chain, including targeted treatment innovation and scalable biomanufacturing powered by innovative...
Loyal is a clinical-stage veterinary biotechnology company dedicated to extending the healthy lifespan of dogs. The company develops pharmaceutical therapies and longevity drugs that target the underlying biological processes of aging to delay the onset of age-associated diseases and preserve quality of life for senior dogs, pioneering a new category of preventative veterinary prescription drugs.
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we...
Regeneron's Top Stability & Growth Strengths
Product Line Growth: The company is growing on financials and products, with momentum attributed to EYLEA HD, Libtayo, and rising Dupixent collaboration revenue alongside shareholder-return actions (dividend and buybacks) reinforcing the trend in 2024–2025.
Future-Ready Strategy: The setup for 2025–2026 includes multiple identified catalysts, including the odronextamab FDA decision (target action date July 30, 2025), further EYLEA HD label/formulation updates, and the ongoing Dupixent COPD rollout as key determinants for sustaining or accelerating growth.
Innovation-Driven Growth: A science-driven platform approach (including VelocImmune, the Regeneron Genetics Center, and advanced proteomics/genomics) is positioned as enabling rapid therapeutic discovery across multiple therapeutic areas, supporting an ongoing pipeline-led growth thesis.
Acino is a Swiss pharmaceutical company headquartered in Zurich, with a clear focus on high-growth markets. We deliver quality pharmaceuticals to promote affordable healthcare and leverage our high-quality pharmaceutical manufacturing capabilities and network to supply leading companies through contract manufacturing and out-licensing. For more information: www.acino.swiss *** By engaging with Acino on LinkedIn (or any other Acino social media channel), you are...
XVET GmbH is a global supplier and GMP+ certified exporter of natural, science-based feed and drinking water additives for animal rearing. Founded in 2002, the company is dedicated to supporting sustainable agriculture and advancing animal welfare, especially within the poultry industry. By providing innovative, antibiotic-reducing solutions, XVET helps producers achieve healthier livestock and higher production quality through a diverse range...
At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative...
Eisai US's Top Stability & Growth Strengths
Strong Market Position & Advantage: Leqembi achieved the first traditional FDA approval among amyloid‑targeting antibodies with broadened Medicare coverage and a home‑use maintenance autoinjector, establishing Eisai as a front‑runner in disease‑modifying Alzheimer’s while Lenvima sustains recognized positions in select oncology indications. Feedback suggests this leadership is reinforced by Eisai leading U.S. commercial execution for Leqembi and ongoing real‑world evidence and access work.
Strong Revenue Growth: Company disclosures point to rising consolidated revenue with Leqembi cited as a key growth engine and the U.S. as its largest market, alongside sequential gains in global Leqembi sales. Evidence indicates the Americas outperformed expectations in recent quarters, with Leqembi and Lenvima highlighted as primary contributors.
Market Expansion: Regulatory and access wins such as EU approval for Leqembi, broadened U.S. Medicare coverage, and additional U.S. administration options (monthly IV maintenance and a weekly subcutaneous autoinjector) signal expanding reach. New U.S. manufacturing capacity and a built‑out Nutley HQ further support scale and market presence.
Founded in 1995 and headquartered in Birmingham, AL with an office in Towson, MD, RxBenefits is the employee benefit industry’s first and only technology-enabled pharmacy benefits optimizer (PBO). Today, we employ more than 700 pharmacy pricing, data, and clinical experts to deliver prescription benefit savings to employee benefit consultants and their self-funded clients. RxBenefits exists to ensure EBC’s can offer...
SubjectWell is a venture-backed technology startup on an unstoppable mission to disrupt patient recruitment for clinical trials, a $100 billion dollar sector. Clinical trials need millions of qualified patient volunteers, but regularly fall behind schedule because patients are unaware of the benefits of clinical trials or even how to get involved. SubjectWell was founded by two entrepreneurs on their third...
Founded in 2007, Spaulding Clinical is a full-service, state-of-the-art paperless Phase I clinical pharmacology unit. The company specializes in IND-enabling clinical pharmacology studies, cardiovascular safety, and clinical proof of concept. They provide comprehensive expertise in study design, medical writing, clinical data management, and biostatistics to help pharmaceutical partners deliver high-quality data and ensure the development of safer drugs.
Verity Pharmaceuticals is a specialty pharmaceutical company focused on commercializing therapeutically relevant prescription medicines, particularly those in short supply or absent from the healthcare environment.
Rapport Therapeutics aims to transform the treatment of neurological disorders through a precision medicine approach, precisely targeting disease-driving neurocircuits by leveraging receptor-associated proteins (RAPs). With this approach, Rapport can overcome the well-established limitations of today’s neuromedicines that act indiscriminately throughout the nervous system, resulting in suboptimal efficacy and burdensome side effects. Leading the hunt for precision medicines is a team...
MDxHealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer and other urologic diseases.
Vetoquinol is an independent international veterinary pharmaceutical company that develops, produces, and distributes veterinary drugs and non-medicinal products for both companion animals and livestock globally. Focused on animal health innovation, it serves a wide range of species including cats, dogs, cattle, and pigs across Europe, the Americas, Africa, the Middle East, Asia, and Oceania.
Innovation. Creativity. Evolution. If these are words you’re passionate about, we should chat. A-dec has a solid foundation and reputation for reliability, but we are in an exciting space. With our compass pointing toward the future, we are growing globally and pushing our boundaries. We are looking for some new teammates with a fresh perspective who know how to play...
Tarrytown Expocare LLC is a long-term care pharmacy that dispenses medicinal preparations to patients in intermediate or skilled nursing facilities and serves IDD communities.
Frontage Laboratories, Inc. is a CRO that provides integrated, science-driven, product development services throughout the drug discovery and development process to enable pharmaceutical and biotechnology companies to achieve their development goals. Comprehensive services include drug metabolism and pharmacokinetics, analytical testing and formulation development, preclinical and clinical trial material manufacturing, bioanalysis, preclinical safety and toxicology assessment and early phase clinical studies....
Frontage Laboratories, Inc's Top Stability & Growth Strengths
Market Expansion: Recent announcements describe expansion of early‑phase clinical capabilities in 2026 alongside new and enlarged sites in Exton, Pennsylvania and Europe, indicating broader geographic reach and capacity. Acquisitions and a rising backlog/future contracted revenue further point to continuing expansion into additional markets and regions.
Product Line Growth: New GMP CRDMO capacity came online with a 46,300‑sq‑ft facility opened in 2025 and fully validated by late 2025, adding nine GMP suites and related labs. The 2026 acquisition of a CAP‑accredited central lab in China and added early‑phase clinical capabilities broaden the service portfolio.
Strong Revenue Growth: Recent interim results show first‑half 2026 revenue up 17.1% year over year with net profit more than doubling, signaling a rebound from prior softness. Purchase orders/backlog also increased versus prior periods, supporting near‑term top‑line momentum.
